胃樂新聯(lián)合蘭索拉唑腸溶膠囊治療消化性胃潰瘍的效果分析

王俊麗

【摘要】 目的 分析胃樂新聯(lián)合蘭索拉唑腸溶膠囊治療消化性胃潰瘍的效果。方法 89例消化性胃潰瘍患者， 將其隨機(jī)分為對(duì)照組（43例）與觀察組（46例）。對(duì)照組給予胃樂新治療， 觀察組在對(duì)照組基礎(chǔ)上加用蘭索拉唑治療。比較兩組治療效果。結(jié)果 治療前兩組腹部隱痛、噯氣反酸、惡心嘔吐、腹瀉腹脹積分比較差異均無統(tǒng)計(jì)學(xué)意義（P>0.05）；治療后兩組各癥狀積分均較治療前明顯下降， 且觀察組低于對(duì)照組， 差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。對(duì)照組不良反應(yīng)發(fā)生率9.30%略低于觀察組13.04%， 但差異無統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論 以胃樂新與蘭索拉唑聯(lián)合治療消化性胃潰瘍效果顯著， 能有效減輕患者潰瘍癥狀， 且不良反應(yīng)發(fā)生率低， 安全性高。

【關(guān)鍵詞】 消化性胃潰瘍；胃樂新；蘭索拉唑

DOI：10.14163/j.cnki.11-5547/r.2017.05.042

Effect analysis of Weilexin combined with lansoprazole enteric-coated capsules in the treatment of pepticgastriculcer WANG Jun-li. Department of Gastroenterology， Jinan City First Peoples Hospital， Jinan 250002， China

【Abstract】 Objective To analyze the effect of Weilexin combined with lansoprazole enteric-coated capsules in the treatment of pepticgastriculcer. Methods A total of 89 pepticgastriculcer patients were randomly divided into control group （43 cases） and observation group （46 cases）. The control group received Weilexin for treatment， and the observation group received lansoprazole on the basis of the control group. Treatment effect was compared in two groups. Results There was no statistically significant difference in abdominal dull pain， belching and acid regurgitation， nausea and vomiting， diarrhea and abdominal distension integral before treatment between two groups （P>0.05）. Both groups had obvious decline in each symptom integral after treatment than before treatment， and the observation group had lower integral than the control group. Their difference had statistical significance （P<0.05）. The control group had incidence of adverse reactions as 9.30%， which was lower than 13.04% in the observation group， but the difference had no statistical significance （P>0.05）. Conclusion Combination of Weilexin and lansoprazole shows significant effect in the treatment of pepticgastriculcer， and it can effectively relieve ulcer symptoms in patients with low incidence of adverse reactions and high safety.

【Key words】 Pepticgastriculcer； Weilexin； Lansoprazole

消化性胃潰瘍是消化科常見炎癥疾病， 主要由胃酸及胃蛋白酶消化自身黏膜所致， 對(duì)胃腸功能和相關(guān)臟器存在較大影響[1-5]。胃潰瘍發(fā)生原因與患者不合理飲食和生活習(xí)慣有關(guān)， 如長期酗酒、抽煙、喝茶或咖啡等均易引發(fā)胃潰瘍[2]。目前， 臨床治療此病多以藥物治療為主， 能有效降低胃酸pH值， 延緩潰瘍， 保護(hù)黏膜組織。現(xiàn)常用藥物有胃樂新、蘭索拉唑、奧美拉唑、康復(fù)新液等[6-8]。本研究現(xiàn)就胃樂新與蘭索拉唑聯(lián)合治療消化性胃潰瘍?nèi)〉玫男ЧM(jìn)行分析， 現(xiàn)報(bào)告如下。

1 資料與方法

1. 1 一般資料 選取2016年5～12月治療的89例消化性胃潰瘍患者， 將其隨機(jī)分為對(duì)照組（43例）和觀察組（46例），

對(duì)照組中男25例， 女18例；年齡25～67歲， 平均年齡（45.89±7.04）歲；潰瘍部位：腸胃部16例、十二指腸20例、復(fù)合型7例。觀察組中男26例， 女20例；年齡26～68歲， 平均年齡（46.75±7.08）歲；潰瘍部位：腸胃部15例、十二指腸21例、復(fù)合型10例。兩組患者一般資料比較差異無統(tǒng)計(jì)學(xué)意義（P>0.05）， 具有可比性。